ANT-GROUP
19.4.2022 15:33:12 CEST | Business Wire | Press release
Ant Group today announced it has achieved carbon neutrality in its own operations (Scopes 1 & 2), according to 2021 emission figures certified by the China Environmental United Certification Center (CEC). This marks the Company’s first major step towards fulfilling the commitments it made in March 2021 to achieve net zero in carbon emissions by 2030 , including providing periodic updates on its progress towards achieving this important goal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005649/en/
According to CEC certified figures, in 2021, Ant Group reduced a total of 37,909.87 tons of CO2 e, equivalent to taking 15,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2 e per kilometer.
To validate its results, the CEC used Carbon Matrix , AntChain’s software-as-a-service (SaaS) product that helps businesses and institutions track and certify corporate carbon emissions on blockchain. The CEC was an official service provider to the 2022 Winter Olympics, measuring the Olympic Committee’s carbon reduction effectiveness.
In 2021, Ant Group achieved carbon neutrality in its own operations (Scopes 1 & 2) through a combination of reductions, substitutions and offsets:
- Reduction: reduced 1,668.60 tons of CO2 e by improving its energy savings and efficiency practices.
- Substitution: avoided 21,883.63 tons of CO2 e through the use of renewable energy.
- Offset: offset 23,159.54 tons of CO2 e through the purchase of China Certified Emission Reductions (CCERs).
“This is a major milestone since we announced our carbon neutrality goal on March 12, 2021,” said Yijie Peng, Vice President of Ant Group. “Leveraging innovative technologies such as blockchain and green computation, we are well underway to achieve an inclusive, green and sustainable future.”
According to Ant Group’s carbon neutrality roadmap, by 2030, the Company will achieve net zero carbon emissions across Scopes 1, 2 and 3. Scope 1 refers to direct emissions as a result of fossil fuel burning from sources Ant Group owns or controls. Scope 2 refers to indirect emissions associated with the purchase of electricity and the use of heating or cooling networks. Scope 3 refers to all other carbon emissions generated along Ant Group’s value chain, such as the use of data centers, business travel and daily commute programs provided by the Company.
In 2021, Ant Group reduced a total of 36,241.27 tons of CO2 e in Scope 3, of which the adoption of green computing technologies contributed to 29,591.48 tons – or about 82% of all the Scope 3 reduction.
Data centers, which are at the core of today’s digital economy, consume a large amount of electricity and generate considerable carbon emissions. Following the adoption of green computing technologies in 2019 – such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling and OceanBase enterprise-level distributed relational database – Ant Group more than doubled the utilization rates of data servers in three years, while meaningfully reducing its carbon footprint.
Ant Group’s remaining Scope 3 carbon emission reductions came from sourcing environmentally friendly office supplies, and encouraging employees to take public transportation or shared rides – including taxis and carpooling for local business travel.
The CEC’s carbon neutrality certificate for Ant Group (in Chinese language only) is publicly available on the Information Platform for Carbon Neutrality , which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005649/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
